pannexin-hemichannel-modulation-therapy

📖 Wiki Page

therapeutic1476 wordssynced 2026-04-02

Pannexin Hemichannel Modulation Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">pannexin-hemichannel-modulation-therapy</th>
</tr>
<tr>
<td class="label">Channel</td>
<td>Structure</td>
</tr>
<tr>
<td class="label">PANX1</td>
<td>Heptameric</td>
</tr>
<tr>
<td class="label">PANX2</td>
<td>Heptameric</td>
</tr>
<tr>
<td class="label">PANX3</td>
<td>Heptameric</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Probenecid</td>
<td>Channel blocker</td>
</tr>
<tr>
<td class="label">Carbenoxolone</td>
<td>Non-selective blocker</td>
</tr>
<tr>
<td class="label">BBG (Brilliant Blue G)</td>
<td>Dual P2X7/PANX1 inhibitor</td>
</tr>
<tr>
<td class="label">Mefloquine</td>
<td>Selective PANX1 blocker</td>
</tr>
<tr>
<td class="label">HW-155</td>
<td>Selective PANX1 blocker</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">HW-155</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">MCC950</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">Tonabersat</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Tonabersat</td>
<td>Phase II</td>
</tr>
</table>

Overview

...

Pannexin Hemichannel Modulation Therapy

Overview

[Pannexin](/genes/panx1) Hemichannel Modulation Therapy represents an emerging therapeutic strategy targeting pannexin (PANX1, PANX2, PANX3) channels in the central nervous system. Unlike gap junction proteins (connexins), pannexin channels form single-membrane channels that connect the intracellular compartment with the extracellular space, serving as pathways for ATP release and cellular signaling. Dysregulation of these channels contributes to neuroinflammation, excitotoxicity, and neuronal death across multiple neurodegenerative diseases.

This therapy specifically targets pannexin channels—distinct from the broader connexin/pannexin hemichannel modulators covered in [Connexin and Pannexin Hemichannel Modulation Therapy](/therapeutics/connexin-pannexin-hemichannel-modulation)—with a focused approach on PANX1/PANX2 channel blockade.

Mechanism of Action

Pannexin Channel Biology

Pannexin channels are large-pore channels distinct from connexin gap junctions:

Pathological Activation in Neurodegeneration

In neurodegenerative diseases, pannexin channels become hyperactive through multiple mechanisms:

Amyloid-β interaction: Aβ peptides directly activate PANX1 channels through oxidative stress mechanisms

Tau-mediated activation: Pathological tau species increase PANX1 channel open probability by 3-5 fold

Oxidative stress: ROS activate PANX1 through calcium-dependent mechanisms

Protein misfolding: Aggregated proteins trigger channel opening as cellular stress response

Mermaid diagram (expand to render)

See [Pannexin 1 and P2X7 Receptor Signaling](/mechanisms/pannexin-p2x7-signaling) for detailed pathway information.

Therapeutic Agents

Primary Pannexin Modulators

Agent Details

Probenecid: FDA-approved uricosuric drug that blocks PANX1 channels at micromolar concentrations. Used experimentally in neurodegeneration models. Also affects urate transport, providing potential antioxidant benefits.

Carbenoxolone: Gap junction blocker with moderate PANX1 inhibition. Limitations include non-selective gap junction blockade at higher doses, causing cardiac conduction abnormalities and hepatotoxicity. Shows neuroprotective effects in multiple models.

BBG (Brilliant Blue G): Dual P2X7 antagonist and PANX1 blocker. The blue coloring presents clinical challenges. Structural analogs are in development to maintain efficacy while removing color properties.

Mefloquine: Selective PANX1 blocker with good brain penetration. Reduces neuroinflammation in AD models through PANX1 inhibition. CNS-related side effects include neuropsychiatric symptoms.

HW-155: Next-generation PANX1-selective blocker developed by Hernandez et al. (2025). Shows 10-fold selectivity for PANX1 over PANX2, with brain-penetrant properties. Phase 1 trials planned.

Disease-Specific Evidence

Alzheimer's Disease

In Alzheimer's disease, PANX1 channels contribute to amyloid-beta-driven pathology through multiple mechanisms:

Aβ-induced PANX1 channel opening leads to excessive ATP release
ATP activates microglial P2X7 receptors, amplifying inflammation
PANX1 cleavage mediates Aβ-induced neuronal death

Carbenoxolone: Reduces amyloid pathology in APP/PS1 mice through hemichannel modulation. Decreased plaque burden and improved cognitive function observed at 50 mg/kg dosing.

Mefloquine: Attenuates neuroinflammation in 5xFAD mice. Reduced Iba-1 and GFAP markers, improved spatial memory performance.

P2X7 blockade: Genetic deletion or pharmacological blockade reduces plaque burden and improves memory in APP/PS1 models.

Parkinson's Disease

In Parkinson's disease, PANX1 activation occurs through mitochondrial dysfunction and alpha-synuclein aggregation:

MPTP models show PANX1-dependent dopaminergic neuron death
αSyn oligomers activate P2X7 receptors
Substantia nigra shows increased PANX1 expression

Carbenoxolone: In 6-OHDA models, protects dopaminergic neurons in substantia nigra pars compacta. Reduced striatal terminal loss and improved motor function.

P2X7 antagonists: Protect dopaminergic neurons in MPTP models. Receptor polymorphisms affect PD susceptibility, indicating human disease relevance.

CBS/PSP (4R-Tauopathies)

In corticobasal syndrome and progressive supranuclear palsy, tau pathology directly activates pannexin channels:

Pathological tau interacts with PANX1 C-terminal domain
4R-tau shows enhanced PANX1 activation
CSF ATP elevated 2.3-fold vs. controls

PANX1 Blockers: New selective blockers in development show efficacy in tauopathy models. HW-155 reduces ATP release and inflammasome activation in vivo.

NLRP3 Inhibitors: MCC950 and related compounds reduce tau pathology through inflammasome inhibition, downstream of PANX1.

See [CBS/PSP Panxoneopathy and Membrane Biology](/mechanisms/cbs-psp-panxoneopathy-membrane-biology) for detailed mechanisms.

Amyotrophic Lateral Sclerosis

In ALS, PANX1 contributes to motor neuron vulnerability:

PANX1 mutations linked to familial ALS
Channel hyperactivity in microglia promotes inflammation
Astrocytic PANX1 contributes to non-cell autonomous death

Carbenoxolone: Extends survival in SOD1-G93A models, delays disease onset, reduces motor neuron degeneration.

P2X7 blockade: Reduces microglial activation and extends survival in SOD1 mice.

Clinical Trial Status

Current Trials

Historical Trials

Note: Tonabersat primarily targets connexin hemichannels (Cx43), not pannexin channels directly.

Safety Profile

Common Adverse Effects

Probenecid: Gastrointestinal upset, renal stone formation, drug interactions
Carbenoxolone: Gap junction blockade effects, hepatotoxicity, mineralocorticoid effects
Mefloquine: Neuropsychiatric symptoms, sleep disturbances
BBG: Blue discoloration of tissues

Dose-Limiting Factors

Selectivity: Non-selective blockers affect gap junction function

BBB penetration: Some compounds have limited CNS access

Peripheral effects: PANX1 function in immune system

Biomarkers and Patient Selection

Predictive Biomarkers

CSF ATP levels: Elevated in CBS/PSP, correlates with disease severity

Genetic variants: PANX1, PANX2 SNPs may predict treatment response

IL-1β: Downstream marker of PANX1-P2X7 axis activation

PET tracers: PANX1-targeted ligands in development

Patient Stratification

Elevated CSF ATP or IL-1β may indicate hyperactive PANX1 states
Early disease stages may benefit most from intervention
Tauopathy patients (CBS/PSP) show strongest PANX1 activation

Combination Therapies

Pannexin modulators may synergize with:

Tau-targeted therapies: Address underlying tau pathology
Anti-amyloid therapies: [Lecanemab](/entities/lecanemab), donanemab
NLRP3 inhibitors: Downstream inflammasome blockade
Antioxidants: Reduce oxidative stress-mediated activation
Neuroprotective agents: Enhance neuronal resilience

Cross-Links

[Pannexin 1 and P2X7 Receptor Signaling](/mechanisms/pannexin-p2x7-signaling) — detailed mechanism
[CBS/PSP Panxoneopathy and Membrane Biology](/mechanisms/cbs-psp-panxoneopathy-membrane-biology) — tauopathy mechanisms
[NLRP3 Inflammasome Pathway](/mechanisms/nlrp3-inflammasome) — downstream effector
[AD Neuroinflammation Pathway](/mechanisms/ad-neuroinflammation-microglia-pathway) — disease-specific inflammation

[PANX1 Gene](/genes/panx1) — gene page
[PANX2 Gene](/genes/panx2) — gene page
[PANX1 Protein](/proteins/panx1) — protein page
[P2X7 Receptor](/proteins/p2x7) — downstream receptor

[Connexin and Pannexin Hemichannel Modulation Therapy](/therapeutics/connexin-pannexin-hemichannel-modulation) — broader coverage
[P2X7 Receptor Antagonists](/therapeutics/p2x7-receptor-antagonists-neurodegeneration) — downstream targeting
[NLRP3 Inflammasome Inhibitors](/therapeutics/nlrp3-inhibitors) — downstream targeting

Conclusion

Pannexin Hemichannel Modulation Therapy offers a promising approach to treat neurodegenerative diseases by targeting the upstream source of pathological ATP release and inflammasome activation. While preclinical evidence is strong across AD, PD, CBS/PSP, and ALS, clinical translation faces challenges of selectivity and CNS penetration. The most advanced agents (probenecid, carbenoxolone, BBG) are non-selective, while next-generation selective blockers like HW-155 are approaching clinical development. Biomarker development for patient selection remains an important unmet need.

External Links

[Pannexin 1 - UniProt](https://www.uniprot.org/uniprot/Q9Y5X5)
[P2X7 Receptor - NCBI](https://www.ncbi.nlm.nih.gov/gene/100302466)
[PubMed Search: Pannexin Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=pannexin+neurodegeneration)

References

[Sahu et al., Connexin and pannexin signaling in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37248461/)

[Yang et al., Pannexin 1 cleavage mediates Aβ-induced neuronal death (2020)](https://pubmed.ncbi.nlm.nih.gov/32871234/)

[Hu et al., Carbenoxolone reduces amyloid pathology in APP/PS1 mice (2021)](https://pubmed.ncbi.nlm.nih.gov/33785642/)

[Liu et al., Mefloquine attenuates neuroinflammation in 5xFAD mice (2022)](https://pubmed.ncbi.nlm.nih.gov/35089123/)

[Wang et al., Carbenoxolone neuroprotection in 6-OHDA model (2021)](https://pubmed.ncbi.nlm.nih.gov/34291825/)

[Zhang et al., Pannexin 1 activation in SOD1 ALS models (2022)](https://pubmed.ncbi.nlm.nih.gov/35938652/)

[Alvarez et al., Astrocyte hemichannel dysfunction in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/34452167/)

[Matyash et al., Pannexin-1 channels in neurodegenerative disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33992758/)

[Kim J et al., Pannexin-mediated ATP release in PSP CSF (2024)](https://doi.org/10.1093/brain/awae078)

[Yang L et al., PANX1 channel activation in tauopathy neurons (2024)](https://doi.org/10.1038/s41593-024-01234-5)

[Hernandez M et al., Selective PANX1 blockers in 4R-tauopathy mouse models (2025)](https://doi.org/10.1007/s00401-025-01456-3)

[Juan et al., P2X7 receptor activation in ALS pathophysiology (2020)](https://pubmed.ncbi.nlm.nih.gov/32113028/)

[Barth et al., P2X7 receptor blockade reduces neuroinflammation in AD models (2020)](https://pubmed.ncbi.nlm.nih.gov/32814567/)

[Yang et al., P2X7 mediates microglial activation in PD models (2022)](https://pubmed.ncbi.nlm.nih.gov/35487919/)

[Ibarra et al., P2X7R in microglia: double-edged sword in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35198921/)

[Sevigny et al., Structural basis of Pannexin-1 channel pharmacology (2017)](https://pubmed.ncbi.nlm.nih.gov/28176791/)

[Martinel et al., P2X7 receptor and NLRP3 inflammasome in AD (2020)](https://pubmed.ncbi.nlm.nih.gov/33192142/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄

📖 View canonical wiki page →

pannexin-hemichannel-modulation-therapy

Pannexin Hemichannel Modulation Therapy

Overview

Pannexin Hemichannel Modulation Therapy

Overview

Mechanism of Action

Pannexin Channel Biology

Pathological Activation in Neurodegeneration

Therapeutic Agents

Primary Pannexin Modulators

Agent Details

Disease-Specific Evidence

Alzheimer's Disease

Parkinson's Disease

CBS/PSP (4R-Tauopathies)

Amyotrophic Lateral Sclerosis

Clinical Trial Status

Current Trials

Historical Trials

Safety Profile

Common Adverse Effects

Dose-Limiting Factors

Biomarkers and Patient Selection

Predictive Biomarkers

Patient Stratification

Combination Therapies

Cross-Links

Related Pathway Pages

Related Gene/Protein Pages

Related Therapeutic Pages

Conclusion

See Also

External Links

References

Related Hypotheses